Keywords
Colitis ulcerative
Inflammation
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of Crohn's Disease (CD) and Ulcerative Colitis (UC). Bibliographic review: Patients with Inflammatory Bowel Diseases (IBD) have impaired quality of daily life, as both diseases have a higher incidence in young patients, who have frequent symptoms of abdominal pain, diarrhea and bloody stools, in addition to weight loss and chronic progression with repeated cycles of relapse and remission. It is believed that they arise from the interaction of four factors: environmental, genetic, microbiota and immunological. IBDs are chronic, autoimmune diseases that may present long periods of remission or frequent relapses, of which the etiology is not known. Final considerations: UC affects the colonic and rectal mucosa continuously, forming erosions and/or ulcers. While CD is characterized by discontinuous involvement with transmural and/or fistula involvement, which can affect any region of the digestive tract, from the mouth to the anus, but mainly the ileocecal and perianal regions. Thus, it is essential to know and differentiate between these diseases in order to provide adequate diagnosis and treatment, improving quality of life.
References
ADAMINA M, et al. O ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis, 2020; 14(2):155-168.
ADEGBOLA SO, et al. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci, 2018; 19(8): 2244.
BRULAND T, et al. Host-Viral Interactions in the Pathogenesis of Ulcerative Colitis. Int J Mol Sci, 2021;22(19):10851.
CARVALHO CL, et al. Doenças inflamatórias intestinais: uma abordagem geral. RevistaEletrônicaAcervoMédico, 2022; 2: e9650.
CHANG J, et al. Crohn's disease initiated with extraintestinal features. BMJ Case Rep, 2019; 12(4):e229916.
DRANGA M, et al. Anemia in Crohn's Disease-The Unseen Face of Inflammatory Bowel Disease. Medicina (Kaunas), 2021; 57(10): 1046.
FERREIRA GS, et al. Fisiopatologia e etiologias das doenças inflamatórias intestinais: uma revisão sistemática de literatura. Brazilian Journal of Health Review, 2021; 4(4): 17061-17076.
FINAMORE A, et al. Salivary Stress/Immunological Markers in Crohn's Disease and Ulcerative Colitis. Int J Mol Sci, 2020; 21(22):8562.
FUMERY M, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol, 2018; 16(3):343-356.
HIGASHIYAMA M, et al. Management of elderly ulcerative colitis in Japan. J Gastroenterol, 2019; 54(7):571-586.
KURCHAZIK T, et al. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. DtschArztebl Int. 2020; 117(33-34): 564-574.
LI N, SHI RH. Updated review on immune factors in pathogenesis of Crohn’s disease. World J Gastroenterol., 2018; 24(1): 15-22.
MATSUOKA K, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol., 2018; 53(3): 305-353.
MEIMA-VAN EMP, et al. Surgical management of Crohn's disease: a state of the art review. Int J Colorectal Dis, 2021; 36(6): 1133-1145.
PASSOS MAT, et al. The Importance of Colonoscopy in Inflammatory Bowel Diseases. Arquivos Brasileiros de Cirurgia Digestiva, 2018; 31 (02): e1374.
PABLA BS, SCHWARTZ DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am., 2020; 49(4): 671-688.
PETAGNA L, et al. Pathophysiology of Crohn's disease inflammation and recurrence. Biol Direct., 2020; 15(1): 23.
PIZARRO G, et al. Prognostic factors of ulcerative colitis at the moment of diagnosis. Rev Med Chil, 2017; 145(10): 1319-1329.
POPOV J, et al. Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies. Int J Mol Sci, 2021; 22(21): 11365.
PRAVDA J. Can ulcerative colitis be cured? Discov Med, 2019; 27(149): 197-200.
RAJBHANDARI R, et al. Crohn's disease in low and lower-middle income countries: A scoping review. World J Gastroenterol, 2020; 26(43): 6891-6908.
SANTOS ALC, et al. Nutritional therapy for inflammatory bowel diseases: Crohn’s disease and ulcerative colitis. Research, Society and Development, 2021; 10(7): e11410716660.
SEGAL JP, et al. Ulcerative colitis: an update. Clin Med (Lond), 2021; 21(2): 135-139.
SENSI B, et al. The Role of Inflammation in Crohn's Disease Recurrence after Surgical Treatment. J Immunol Res, 2020; 2020: 8846982.
SEYEDIAN SS, et al. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life, 2019; 12(2): 113-122.
TAKENAKA K, et al. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol. 2020; 55(6): 579-587.
UNGARO RC, et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment PharmacolTher, 2020; 51(9): 831-842.
VASCONCELOS RS, et al. Qualidade de vida de pacientes com doença inflamatória intestinal: revisão integrativa. ESTIMA, Braz. J. EnterostomalTher., 2018; 16: e2118.
VEAUTHIER B, HORNECKER JR. Crohn's Disease: Diagnosis and Management. Am Fam Physician, 2018; 98(11): 661-669.
YAMAMOTO-FUROSHO JK, et al. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Rev Gastroenterol Mex (Engl Ed), 2018; 83(2): 144-167.
ZHOU WP, et al. Economic burden and factors associated with Crohn's disease. Beijing Da XueXueBao Yi Xue Ban, 2021; 53(3): 555-559.